My is BSF-106 anBSPP remains around 150 .My... - Diabetes India
My is BSF-106 anBSPP remains around 150 .My doc. recommended Metafort 500 but now Diamicron MR . Which is better ?
don't say like indulge in mindless walking for controlling sugar levels..walk is must for daibatic patient must minimum 30 minutes that to early morning with empty stomach
Staying indoor you can do yoga exercises requiring half time of walking.Nobody will object to your burning out excess calories by sweating exertions !!
Walking or other excercise is required for diabetics and also for non diabetics to control fat/weight. Fat control, and weight control is required by all.
Metafort 500 or Diamicron MR . Which is better ?
Related MIMS Class: Antidiabetic Agents
Diamicron (Sulfonylureas) & Metafort 500 (metformin) in the spotlight
Malvinderjit Kaur Dhillon
When used as first-line therapy for patients with type 2 diabetes (T2D), sulfonylureas increase the risk of death compared with standard first-line metformin treatment, according to study data presented at the 49th European Association for the Study of Diabetes (EASD) annual meeting recently held in Barcelona, Spain.
Lead author of the study, Professor Craig Currie from Cardiff University’s School of Medicine in Cardiff, Wales, urged physicians to consider the potential hazard of prescribing sulfonylureas in such a manner.
Currie and his team of researchers looked at retrospective data extracted from the Clinical Practice Research Datalink (CPRD), a data set made up of more than 10 million patients treated in primary care in the UK. Patients with T2D who were put on first-line glucose-lowering treatments between 2000 and 2012 were selected. The primary endpoint of the study was all-cause mortality.
The team identified 76,811 patients who were treated with metformin monotherapy and 15,687 with sulfonylurea monotherapy. A matched-cohort study was performed comparing the two treatment groups after a mean follow-up of 3 years.
The analysis showed there were 3,209 deaths in the metformin group, while the sulfonylurea group saw 2,172 deaths. This translated to 13.6 percent deaths per 1,000 person-years in the metformin group and 44.6 percent deaths per 1,000 person-years in the sulfonylurea group. [Adjusted hazard ratio 1.58, 95% CI 1.48 to 1.68, p<0.001]
“There are significant differences between the patients prescribed metformin and sulfonylurea at baseline and this will obviously explain the difference in mortality to an extent. However, the increased mortality in the sulfonylurea group remained after the data was adjusted with a Cox model in two different matching approaches base on direct matching and propensity scoring and in subgroup analyses. It didn’t matter if the patient was younger or older, male or female, morbid or less morbid and well controlled or poorly controlled. The hazard ratios were all about the same,” said Currie.
“In my view, the safety of sulfonylureas needs urgent evaluation because potentially we are increasing the risk of all-cause mortality,” said Currie.
In addressing questions on why sulfonylurea is still being prescribed if there are significant risks, Currie commented that this is worrying as not all general practitioners or other doctors are fully informed about the risks of commonly used drugs.
He also noted that this particular data go back to 2000, when the study was started. Traditionally, patients were commonly prescribed with sulfonylurea as first-line treatment rather than with metformin.
Dr. Andreas Pfeiffer, of the Charité Universitätsmedizin, Berlin, Germany, said that some patients switch to sulfonylurea as they are unable to tolerate metformin and that this is the case in about 15 percent of diabetic patients.
Currie also discussed results from a second study which compared 33,893 patients who received second-line combination therapy of sulfonylurea and metformin with 7,864 patients who were treated with a metformin and DPP-4 inhibitor combination.
Analysis found that there were 16.9 percent deaths per 1,000 person-years in the sulfonylurea/metformin group and 7.3 percent deaths per 1,000 person years in the metformin/DPP-4 inhibitor group.
“The DPP-4 inhibitors in combination with metformin were safe compared to a metformin and sulfonylurea combination, the most common second-line glucose lowering regimen. I doubt the DPP-4s are ‘wonder drugs’ but the difference in mortality has more to do with sulfonylurea causing an increase in insulin and other issues [cardiovascular events],” said Currie.
It is interesting to note that in the Action in Diabetes and Vascular disease: PreterAx and DiamicroN Controlled Evaluation (ADVANCE) study results, which were announced at the 2008 EASD Congress in Rome, the use of gliclazide modified-release saw no increase in mortality in over 10,000 participants with T2D. This could suggest that the type of sulfonylurea prescribed might influence mortality risk.
mims.com/India/pub/topic/Me...
Hello DrBSTaneja, Can you please clarify the product mentioned here as 20micronsherbal.com. is the one you are detailing in your article. Thanks for the survey details- But, i could not understand the DPP-4 inhibitor combination and sulfonylurea and metformin combination -present in this drug.
Thanks and regards.
Yoga or walking are essential.. Even u have walked. Do not post statements just like that with out assessment. Here people take the information and may practice as they like and easy.
